Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.44 |
| ▸ | PRCP | P42785 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260676 | 1.00 | HCRTR1 (0.44) | HCRTR1HCRTR2PRCPGRM5KDM4E | |
| SCHEMBL2777098 | 0.93 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL2776668 | 0.88 | PRCP (0.41) | HCRTR1HCRTR2PRCPHTR2B | |
| SCHEMBL2778773 | 0.86 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL1836139 | 0.86 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL2777502 | 0.85 | PRCP (0.46) | PRCP | |
| SCHEMBL9605169 | 0.83 | USP30 (0.51) | HCRTR1HCRTR2HTR2B | |
| SCHEMBL2779204 | 0.83 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL2775522 | 0.82 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL2777787 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | claimed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | claimed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | claimed |
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | HCRTR1 4453/4885HCRTR2 4639/4885PRCP 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.